Understanding resistance in multiple myeloma
MYeloma Resistance And Clonal Evolution
Nantes University Hospital · NCT03807128
This study is trying to understand why some people with multiple myeloma don’t respond to treatment by collecting data and blood samples from patients at specialized cancer centers in Northwestern France.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1400 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Nantes University Hospital (other) |
| Locations | 2 sites (La Roche-sur-Yon and 1 other locations) |
| Trial ID | NCT03807128 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients diagnosed with multiple myeloma (MM) at specialized oncology centers in Northwestern France. It aims to gather comprehensive data on the biological mechanisms of therapeutic resistance, as well as predictors of this resistance, through continuous follow-up and collection of socio-economic, medical, and quality of life information. Participants will also provide blood samples for analysis to identify potential biomarkers and improve diagnostics. The study includes all patients over 18 years old diagnosed with MM, ensuring a diverse cohort for better insights.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old diagnosed with multiple myeloma.
Not a fit: Patients under 18 years old or those under guardianship will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of multiple myeloma, potentially enhancing patient outcomes.
How similar studies have performed: While studies on multiple myeloma have been conducted, this specific approach focusing on resistance mechanisms and quality of life is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient consulting due to the discovery or recurrence of MM according to international diagnostic criteria (IMWG 2014) * Patient having consented to participate in the study and his/her biocollection * Patient affiliated to or benefiting from a social security scheme or similar Exclusion Criteria: * Minors * Major under guardianship or curatorship * Protected persons. * Pregnant or breast-feeding women * Persons benefiting from the AME
Where this trial is running
La Roche-sur-Yon and 1 other locations
- La Roche sur Yon Hospital Departmental — La Roche-sur-Yon, France (RECRUITING)
- Nantes University Hospital — Nantes, France (RECRUITING)
Study contacts
- Principal investigator: Cyrille TOUZEAU, PU — Nantes University Hospital
- Study coordinator: Cyrille TOUZEAU, PU
- Email: cyrille.touzeau@chu-nantes.fr
- Phone: 02 40 08 32 71
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Multiple Myeloma, Myeloma, Cohort, Resistance, Quality of life